Guest LCSC Info Posted January 10, 2012 Share Posted January 10, 2012 Dr. Ross Camidge on ALK Inhibitor XALKORI, Who To Screen, and Other Therapies for ALK-Positive NSCLC http://blog.lungevity.org/2011/11/16/dr ... ive-nsclc/ November 16th, 2011 - by Dr. Jack West Recently, Drs. Ross Camidge and Ben Solomon joined us for a webinar on the subject of “ALK Inhibition: From Biology to FDA-Approved Therapy for Advanced NSCLC”. Following Dr. Solomon’s great summary of the biology and early clinical experience with the ALK inhibitor XALKORI (crizotinib) in ALK-positive patients (about 4% of the NSCLC population), Dr. Camidge guided us through the practical implications of this work. Specifically, now with a newly FDA-approved therapy of XALKORI tied to a rather uncommon molecular marker, who should we be screening? And since patients who respond to XALKORI appear to become resistant over time, what are the subsequent options for these ALK-positive patients with acquired resistance to XALKORI, or who are unable to get it in the first place? Click on the blog link above to find the podcast by Dr. Camidge in audio and video formats, as well as the associated transcript and figures. I’ll soon be posting the question and answer session from this webinar program, which is being edited now. Between now and then, I’ll next be moving from Ross to a newly-identified mutation called ROS-1 and worked on largely by…(can you guess?) Dr. Ross Camidge — though this mutation is apparently not named for him. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.